Last mentioned: Mar 17, 2026
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
Quarterly Earnings Release
Official financial results and conference calls scheduled for both companies.
Pre-Earnings Market Activity
Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
Takeda Deal Restructuring
Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
Institutional Exit
SEC filings reveal a $170 million position liquidation by a major fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
J&J Milestone
Protagonist receives $231M milestone payment for icotrokinra progress.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.